Why the study?
NAFPD, NAFLD, and PAT are often associated with T2DM, but their incidence and the effect of metformin treatment on them in new-onset T2DM required evaluation.
Does metformin therapy reduce fat accumulation in the liver, pancreas, and pericardium in patients with new-onset type 2 diabetes mellitus?
Does metformin therapy reduce fat accumulation in the liver, pancreas, and pericardium in patients with new-onset type 2 diabetes mellitus?
Metformin therapy reduces hepatic fat accumulation but not pancreatic or pericardial fat in patients with new-onset type 2 diabetes.
Answers are grounded in this paper and cite their sources.
Metformin reduced liver fat but not pancreatic or pericardial fat in small NODM cohort; leaves open whether treatment modifies ectopic adiposity.
Background: Nonalcoholic fatty pancreas and liver disease (NAFPD and NAFLD) and pericardial adipose tissue (PAT) are often associated with type 2 diabetes mellitus (T2DM). Our aim was to evaluate the incidence rate of NAFLD and NAFPD, PAT size, and the effect of metformin treatment on NAFLD, NAFPD, and PAT in new-onset T2DM (NODM). Methods: Seventeen patients with NODM and 10 subjects used as a control group were involved in the study. Computed tomography (CT) and laboratory tests were performed before the beginning of metformin therapy and 4 months afterward. PAT and the amount of fat in the pancreas and liver were determined by X-ray attenuation during unenhanced CT examination and compared with the values for the control subjects. Results: Metabolic parameters improved significantly after metformin therapy. NAFLD was diagnosed in 64.7% of the patients with NODM and in 10% of the control subjects. The radiation absorption of the liver was significantly lower in the patients with NODM compared with the control group and significantly higher after metformin therapy compared with the baseline values. Only six patients (35.3%) had NAFLD after metformin therapy. NAFPD was diagnosed in 82.3% of the patients with NODM and in 20% of the control subjects. The radiation absorption of the pancreas was significantly lower in the patients with NODM compared with the control group but did not change significantly after treatment. PAT size was significantly larger in the patients with NODM and did not change significantly after metformin treatment. Conclusions: NAFLD, NAFPD, and increased PAT were detected in the majority of patients with NODM. Metformin therapy decreased the amount of fat in the liver in parallel with an improvement in the metabolic parameters and may, thus, be beneficial for preventing the late consequences of NAFLD.
No takes yet. Share an insight, caveat, or question.
Zsóri et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: